{"artifact":{"id":"experiment-exp-9d2d59a7-8bc0-4399-aab0-2538f3a07b6f","artifact_type":"experiment","entity_ids":"[\"NLRP3,APOE\"]","title":"RBG treatment in ApoE-/- atherosclerosis mouse model","quality_score":0.9,"created_by":"experiment_extractor","provenance_chain":"[]","content_hash":"aa0a5cbc03ad48bd15291b32b6e46827b44c103100e94d9b7ba04fce25ca87f2","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-11T00:50:00.424611"},"p_value":null,"protocol":"ApoE-/- mice were treated with RBG, followed by assessment of body weight, atherosclerotic plaque formation, serum lipid profiles, and inflammatory marker expression through transcriptomics and molecular biology techniques","effect_size":null,"sample_size":null,"source_pmid":"40258472","extracted_at":"2026-04-10T17:50:00.421419","_schema_version":1,"experiment_type":"animal_model","success_criteria":"reduction in plaque size, improved lipid profiles, decreased inflammatory markers","expected_outcomes":"RBG treatment was expected to reduce atherosclerotic plaque formation and inflammatory responses. Results showed reduced body weight, smaller atherosclerotic plaques, improved serum lipid profiles, and suppressed expression of inflammatory markers including NLRP3","statistical_methods":null},"created_at":"2026-04-11T00:50:00-07:00","updated_at":"2026-04-11T00:50:00-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-11T00:50:00-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"7c95186f-98b6-4bda-b3d9-7d1d5430b87c","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"experiment_extractor"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"experiment-exp-ece43796-b1b4-4248-9af3-e7cad622a114","link_type":"related","strength":0.3333333333333333,"evidence":null},{"target_artifact_id":"wiki-nlrp3","link_type":"related","strength":0.3333333333333333,"evidence":null},{"target_artifact_id":"wiki-proteins-nlrp3","link_type":"related","strength":0.3333333333333333,"evidence":null},{"target_artifact_id":"experiment-exp-8c4df498-6bf5-43f0-a8b5-f742a5159986","link_type":"related","strength":0.3333333333333333,"evidence":null},{"target_artifact_id":"experiment-exp-9dd2904f-446c-423e-843a-e7e2b8a57b9b","link_type":"related","strength":0.3333333333333333,"evidence":null},{"target_artifact_id":"wiki-hypotheses-nlrp3-inflammasome-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-cell-types-apoe-expressing-astrocytes","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-cell-types-nlrp3-inflammasome-activated-microglia","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-hypotheses-apoe-contributes-alzheimer's-disease-regulat","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-genes-apoe","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-entities-nlrp3-inflammasome","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-hypotheses-apoe-contributes-alzheimers-disease-regulat","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-diagnostics-apoe-genotyping","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-cell-types-nrlp3-activated-microglia","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-pathway-neurodegeneration","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-proteins-apoe","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-activation-pathway","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inflammasome-inhibitors","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-experiments-nlrp3-inflammasome-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inhibitor-early-pd-trial","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-ad-pathway","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-apoe-lipid-metabolism-alzheimers","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-neurodegeneration","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-senomorphic-cycling","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-proteins-nlrp3-protein","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-ideas-nlrp3-senomorphic-cycling-therapy","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-apoe-lipid-dysregulation-cognitive-decline-causal-chain","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-inhibitors-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-therapeutics-apoe-genotype-guided-prevention","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: APOE"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-neurodegeneration","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-investment-nlrp3-inflammasome","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inhibitors","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"}],"incoming_links":[{"source_artifact_id":"wiki-hypotheses-nlrp3-inflammasome-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-cell-types-apoe-expressing-astrocytes","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-cell-types-nlrp3-inflammasome-activated-microglia","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-hypotheses-apoe-contributes-alzheimer's-disease-regulat","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-genes-apoe","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-entities-nlrp3-inflammasome","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-hypotheses-apoe-contributes-alzheimers-disease-regulat","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-diagnostics-apoe-genotyping","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-cell-types-nrlp3-activated-microglia","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-pathway-neurodegeneration","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-proteins-apoe","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-activation-pathway","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inflammasome-inhibitors","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-proteins-nlrp3","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-experiments-nlrp3-inflammasome-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inhibitor-early-pd-trial","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-ad-pathway","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-apoe-lipid-metabolism-alzheimers","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-neurodegeneration","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-senomorphic-cycling","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-proteins-nlrp3-protein","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-ideas-nlrp3-senomorphic-cycling-therapy","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-apoe-lipid-dysregulation-cognitive-decline-causal-chain","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-inhibitors-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-therapeutics-apoe-genotype-guided-prevention","link_type":"mentions","strength":0.8,"evidence":"Gene target: APOE"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-neurodegeneration","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-investment-nlrp3-inflammasome","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inhibitors","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-entities","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/entities"},{"source_artifact_id":"wiki-experiments","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments"},{"source_artifact_id":"wiki-ideas","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/ideas"},{"source_artifact_id":"wiki-therapeutics-dietary-interventions-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-dietary-interventions-parkinsons"},{"source_artifact_id":"wiki-therapeutics-ad-pd-target-comparison-matrix","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-ad-pd-target-comparison-matrix"},{"source_artifact_id":"wiki-therapeutics-csf1r-inhibitors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-csf1r-inhibitors-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-tgf-beta-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-tgf-beta-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-p2x7-receptor-antagonists-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 19x in wiki/therapeutics-p2x7-receptor-antagonists-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-nadph-oxidase-inhibitors","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-nadph-oxidase-inhibitors"},{"source_artifact_id":"wiki-therapeutics-ketogenic-diet-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-ketogenic-diet-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-4r-tauopathy-targets","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-4r-tauopathy-targets"},{"source_artifact_id":"wiki-therapeutics-autophagy-inducers-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-autophagy-inducers-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-hyperbaric-oxygen-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-hyperbaric-oxygen-therapy"},{"source_artifact_id":"wiki-therapeutics-kamuvudine-9-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-kamuvudine-9-alzheimers"},{"source_artifact_id":"wiki-therapeutics-alpha-synuclein-targeting-therapies","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-alpha-synuclein-targeting-therapies"},{"source_artifact_id":"wiki-therapeutics-synaptic-plasticity-therapeutics-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-synaptic-plasticity-therapeutics-pd"},{"source_artifact_id":"wiki-therapeutics-galectin-3-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-galectin-3-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-supplements-guide-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-supplements-guide-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-pannexin-hemichannel-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/therapeutics-pannexin-hemichannel-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-section-99-purinergic-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/therapeutics-section-99-purinergic-signaling"},{"source_artifact_id":"wiki-therapeutics-section-147-neuroimmune-glial-crosstalk-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-section-147-neuroimmune-glial-crosstalk-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-alpha-lipoic-acid-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-alpha-lipoic-acid-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-mtor-inhibitor-therapy-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-mtor-inhibitor-therapy-parkinsons"},{"source_artifact_id":"wiki-therapeutics-carbon-monoxide-therapy-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-carbon-monoxide-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-senolytic-therapies-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-senolytic-therapies-parkinsons"},{"source_artifact_id":"wiki-therapeutics-microglia-modulation-therapies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/therapeutics-microglia-modulation-therapies"},{"source_artifact_id":"wiki-therapeutics-immune-drug-repurposing-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-immune-drug-repurposing-parkinsons"},{"source_artifact_id":"wiki-therapeutics-urolithin-a-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-urolithin-a-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-pyroptosis-inhibition-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 33x in wiki/therapeutics-pyroptosis-inhibition-therapy"},{"source_artifact_id":"wiki-therapeutics-cbs-psp-daily-action-plan","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-cbs-psp-daily-action-plan"},{"source_artifact_id":"wiki-therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-section-118-neuroinflammation-imaging-advanced-cbs-psp","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-section-118-neuroinflammation-imaging-advanced-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-anti-inflammatory-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-anti-inflammatory-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-microglia-modulation-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-microglia-modulation-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-microglial-priming-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-microglial-priming-therapy"},{"source_artifact_id":"wiki-therapeutics-intermittent-fasting-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-intermittent-fasting-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-sulforaphane-nrf2-neuroprotection","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-sulforaphane-nrf2-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-p2x7-receptor-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/therapeutics-p2x7-receptor-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-cbs-psp-nutritional-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cbs-psp-nutritional-therapy"},{"source_artifact_id":"wiki-therapeutics-multi-target-pharmacotherapy-cbs-psp","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-multi-target-pharmacotherapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-spermidine-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-spermidine-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-cgrp-receptor-modulators-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cgrp-receptor-modulators-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-exosome-based-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-exosome-based-therapeutics"},{"source_artifact_id":"wiki-therapeutics-urolithin-a-mitophagy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-urolithin-a-mitophagy"},{"source_artifact_id":"wiki-therapeutics-s100-protein-modulator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-s100-protein-modulator-therapy"},{"source_artifact_id":"wiki-therapeutics-treatment-pipeline","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-treatment-pipeline"},{"source_artifact_id":"wiki-therapeutics-ketone-body-therapy-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-ketone-body-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-nutritional-therapy-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-nutritional-therapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-mitochondrial-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-mitochondrial-therapeutics"},{"source_artifact_id":"wiki-therapeutics-metformin-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-metformin-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-neuroinflammation-modulation-therapies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/therapeutics-neuroinflammation-modulation-therapies"},{"source_artifact_id":"wiki-therapeutics-sirtuin-modulators-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-sirtuin-modulators-parkinsons"},{"source_artifact_id":"wiki-therapeutics-sglt2-inhibitors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-sglt2-inhibitors-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-parp-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-parp-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-cgas-sting-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cgas-sting-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-galectin-3-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-galectin-3-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-rage-modulator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-rage-modulator-therapy"},{"source_artifact_id":"wiki-therapeutics-irisin-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-irisin-therapy"},{"source_artifact_id":"wiki-therapeutics-neurodegeneration-therapeutic-target-comparison-matrix","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-neurodegeneration-therapeutic-target-comparison-matrix"},{"source_artifact_id":"wiki-therapeutics-dpp-4-inhibitor-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-dpp-4-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-glp-1-receptor-agonists-parkinsons"},{"source_artifact_id":"wiki-therapeutics-cd47-sirp-alpha-immune-checkpoint-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/therapeutics-cd47-sirp-alpha-immune-checkpoint-therapy"},{"source_artifact_id":"wiki-therapeutics-creatine-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-creatine-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-nicotinamide-riboside","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-nicotinamide-riboside"},{"source_artifact_id":"wiki-therapeutics-vitamin-d-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-vitamin-d-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-corticobasal-degeneration-treatment","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-corticobasal-degeneration-treatment"},{"source_artifact_id":"wiki-therapeutics-cuatsm","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cuatsm"},{"source_artifact_id":"wiki-therapeutics-melatonin-tauopathy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-melatonin-tauopathy"},{"source_artifact_id":"wiki-therapeutics-aim2-inflammasome-modulator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-aim2-inflammasome-modulator-therapy"},{"source_artifact_id":"wiki-therapeutics-h2s-releasing-compounds-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-h2s-releasing-compounds-parkinsons"},{"source_artifact_id":"wiki-therapeutics-neuroinflammation-targeting-therapies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 24x in wiki/therapeutics-neuroinflammation-targeting-therapies"},{"source_artifact_id":"wiki-therapeutics-tudca-udca-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-tudca-udca-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-omega-3-fatty-acids-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-omega-3-fatty-acids-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-specialized-pro-resolving-mediator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-specialized-pro-resolving-mediator-therapy"},{"source_artifact_id":"wiki-therapeutics-csf1r-inhibitors-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-csf1r-inhibitors-parkinsons"},{"source_artifact_id":"wiki-therapeutics-chemokine-receptor-modulation-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-chemokine-receptor-modulation-parkinsons"},{"source_artifact_id":"wiki-therapeutics-ibudilast","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-ibudilast"},{"source_artifact_id":"wiki-therapeutics-dapansutrile-parkinsons-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 63x in wiki/therapeutics-dapansutrile-parkinsons-disease"},{"source_artifact_id":"wiki-therapeutics-cue1-device-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cue1-device-pd"},{"source_artifact_id":"wiki-therapeutics-specialized-pro-resolving-mediator-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-specialized-pro-resolving-mediator-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-molecular-hydrogen-therapy-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-molecular-hydrogen-therapy-parkinsons"},{"source_artifact_id":"wiki-entities-apoptosis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/entities-apoptosis"},{"source_artifact_id":"wiki-therapeutics-syk-kinase-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-syk-kinase-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-omega-3-fatty-acids-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-omega-3-fatty-acids-parkinsons"},{"source_artifact_id":"wiki-therapeutics-calorie-restriction-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-calorie-restriction-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-pyroptosis-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/therapeutics-pyroptosis-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-minocycline-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-minocycline-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-anti-tau-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-anti-tau-therapeutics"},{"source_artifact_id":"wiki-therapeutics-p2x7-receptor-antagonists-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-p2x7-receptor-antagonists-parkinsons"},{"source_artifact_id":"wiki-therapeutics-microglial-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-microglial-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-gut-microbiome-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-gut-microbiome-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-endosomal-lysosomal-trafficking-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-endosomal-lysosomal-trafficking-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-adenosine-a2a-receptor-antagonists-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-adenosine-a2a-receptor-antagonists-pd"},{"source_artifact_id":"wiki-therapeutics-sodium-oligomannate-gv971","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-sodium-oligomannate-gv971"},{"source_artifact_id":"wiki-clinical-trials-mk-1167-merck-phase-2-ad-nct06721156","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-mk-1167-merck-phase-2-ad-nct06721156"},{"source_artifact_id":"wiki-clinical-trials-cbd-ad-prevention-nct05822362","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-cbd-ad-prevention-nct05822362"},{"source_artifact_id":"wiki-clinical-trials-ct1-dap001-ips-dopaminergic-progenitors-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-ct1-dap001-ips-dopaminergic-progenitors-pd"},{"source_artifact_id":"wiki-clinical-trials-tbu006-parkinson-phase-2a-nct06773962","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-tbu006-parkinson-phase-2a-nct06773962"},{"source_artifact_id":"wiki-clinical-trials-nct05266417-nose-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct05266417-nose-pd"},{"source_artifact_id":"wiki-clinical-trials-commets-semaglutide-mci-nct06072963","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-commets-semaglutide-mci-nct06072963"},{"source_artifact_id":"wiki-clinical-trials-apocynin-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-apocynin-pd"},{"source_artifact_id":"wiki-clinical-trials-move-brain-pd-nct07299279","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-move-brain-pd-nct07299279"},{"source_artifact_id":"wiki-clinical-trials-nct06365190-rtms-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-nct06365190-rtms-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06954662-amino-acid-supplement-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct06954662-amino-acid-supplement-pd"},{"source_artifact_id":"wiki-clinical-trials-ab-1005-gdnf-gene-therapy-regenerate-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-ab-1005-gdnf-gene-therapy-regenerate-pd"},{"source_artifact_id":"wiki-clinical-trials-retigabine-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-retigabine-pd"},{"source_artifact_id":"wiki-clinical-trials-pexidartinib-plx3397-csf1r-parkinsons-nct04888966","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-pexidartinib-plx3397-csf1r-parkinsons-nct04888966"},{"source_artifact_id":"wiki-clinical-trials-nct07308418-vibrotactile-stimulation-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct07308418-vibrotactile-stimulation-pd"},{"source_artifact_id":"wiki-clinical-trials-intranasal-insulin-glutathione-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-intranasal-insulin-glutathione-pd"},{"source_artifact_id":"wiki-clinical-trials-biib122-luma-lrrk2-inhibitor-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-biib122-luma-lrrk2-inhibitor-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06687837-autologous-dopaminergic-neurons-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct06687837-autologous-dopaminergic-neurons-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06821230-dyadic-mindfulness-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct06821230-dyadic-mindfulness-pd"},{"source_artifact_id":"wiki-clinical-trials-xenon-gas-inhalation-neuroinflammation-nct06945614","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/clinical-trials-xenon-gas-inhalation-neuroinflammation-nct06945614"},{"source_artifact_id":"wiki-clinical-trials-uab-tspo-pet-neuroinflammation-pd-nct03457493","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-uab-tspo-pet-neuroinflammation-pd-nct03457493"},{"source_artifact_id":"wiki-clinical-trials-metformin-add-on-levodopa-pd-nct07055958","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-metformin-add-on-levodopa-pd-nct07055958"},{"source_artifact_id":"wiki-clinical-trials-valacyclovir-hsv1-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-valacyclovir-hsv1-pd"},{"source_artifact_id":"wiki-clinical-trials-nct07094516-novartis-alzheimers-phase2","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-nct07094516-novartis-alzheimers-phase2"},{"source_artifact_id":"wiki-clinical-trials-mr-guided-focused-ultrasound-gcase-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-mr-guided-focused-ultrasound-gcase-pd"},{"source_artifact_id":"wiki-clinical-trials-pde4-inhibitor-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-pde4-inhibitor-pd"},{"source_artifact_id":"wiki-clinical-trials-ne3107-bezisterim-early-parkinsons-nct06757010","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-ne3107-bezisterim-early-parkinsons-nct06757010"},{"source_artifact_id":"wiki-clinical-trials-tb006-parkinson","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-tb006-parkinson"},{"source_artifact_id":"wiki-clinical-trials-nouvneu001-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nouvneu001-pd"},{"source_artifact_id":"wiki-clinical-trials-vibrotactile-coordinated-reset-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-vibrotactile-coordinated-reset-pd"},{"source_artifact_id":"wiki-clinical-trials-dapansutrile-pd-nct07157735","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 37x in wiki/clinical-trials-dapansutrile-pd-nct07157735"},{"source_artifact_id":"wiki-clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597"},{"source_artifact_id":"wiki-clinical-trials-bacillus-subtilis-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-bacillus-subtilis-pd"},{"source_artifact_id":"wiki-clinical-trials-purinergic-receptor-trials-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-purinergic-receptor-trials-parkinsons"},{"source_artifact_id":"wiki-hypotheses-post-acute-viral-reservoir-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/hypotheses-post-acute-viral-reservoir-parkinsons"},{"source_artifact_id":"wiki-hypotheses-tryptophan-kynurenine-neurotoxicity-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/hypotheses-tryptophan-kynurenine-neurotoxicity-parkinsons"},{"source_artifact_id":"wiki-hypotheses-stress-granule-dysfunction-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/hypotheses-stress-granule-dysfunction-parkinsons"},{"source_artifact_id":"wiki-hypotheses-pathologic-synergy-occurring-amygdala-betwe","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/hypotheses-pathologic-synergy-occurring-amygdala-betwe"},{"source_artifact_id":"wiki-hypotheses-cgas-sting-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/hypotheses-cgas-sting-parkinsons"},{"source_artifact_id":"wiki-hypotheses-gap-junction-dysfunction-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/hypotheses-gap-junction-dysfunction-parkinsons"},{"source_artifact_id":"wiki-hypotheses-ferroptosis-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/hypotheses-ferroptosis-parkinsons"},{"source_artifact_id":"wiki-hypotheses-purinergic-signaling-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/hypotheses-purinergic-signaling-parkinsons"},{"source_artifact_id":"wiki-datasets-amp-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/datasets-amp-pd"},{"source_artifact_id":"wiki-ideas-cns-nlrp3-inflammasome-inhibitor","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 21x in wiki/ideas-cns-nlrp3-inflammasome-inhibitor"},{"source_artifact_id":"wiki-ideas-payload-aim2-inflammasome-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/ideas-payload-aim2-inflammasome-modulation-therapy"},{"source_artifact_id":"wiki-ideas-cgas-sting-pathway-inhibitor","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-cgas-sting-pathway-inhibitor"},{"source_artifact_id":"wiki-ideas-payload-gasdermin-inhibition-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 16x in wiki/ideas-payload-gasdermin-inhibition-therapy"},{"source_artifact_id":"wiki-investment-peptide-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-peptide-therapeutics"},{"source_artifact_id":"wiki-ideas-payload-trem1-trem2-balanced-microglial-modulation-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-payload-trem1-trem2-balanced-microglial-modulation-therapy"},{"source_artifact_id":"wiki-ideas-combo-nlrp3-cd47-immune-reprogramming","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 28x in wiki/ideas-combo-nlrp3-cd47-immune-reprogramming"},{"source_artifact_id":"wiki-ideas-combination-logic-ideas","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-combination-logic-ideas"},{"source_artifact_id":"wiki-ideas-novel-therapy-index","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/ideas-novel-therapy-index"},{"source_artifact_id":"wiki-ideas-lrrk2-kinase-modulation-prevention","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-lrrk2-kinase-modulation-prevention"},{"source_artifact_id":"wiki-ideas-gpnmb-lipid-laden-microglia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-gpnmb-lipid-laden-microglia"},{"source_artifact_id":"wiki-ideas-multi-target-synergistic-combination-therapy-framework","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-multi-target-synergistic-combination-therapy-framework"},{"source_artifact_id":"wiki-ideas-payload-nfkb-pathway-inhibition-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-payload-nfkb-pathway-inhibition-neurodegeneration"},{"source_artifact_id":"wiki-ideas-glial-therapeutics-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/ideas-glial-therapeutics-neurodegeneration"},{"source_artifact_id":"wiki-ideas-payload-irak4-kinase-modulation-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-payload-irak4-kinase-modulation-therapy"},{"source_artifact_id":"wiki-ideas-yap-taz-mechanoactivation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-yap-taz-mechanoactivation-therapy"},{"source_artifact_id":"wiki-ideas-payload-ipsc-microglia-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/ideas-payload-ipsc-microglia-therapy"},{"source_artifact_id":"wiki-ideas-payload-ufm1ylation-proteostasis-restoration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-payload-ufm1ylation-proteostasis-restoration"},{"source_artifact_id":"wiki-ideas-payload-anti-herpetic-viral-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/ideas-payload-anti-herpetic-viral-therapy-neurodegeneration"},{"source_artifact_id":"wiki-ideas-biomarker-ykl40-antiinflammatory-cycling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-biomarker-ykl40-antiinflammatory-cycling"},{"source_artifact_id":"wiki-investment-microbiome-based-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-microbiome-based-therapeutics"},{"source_artifact_id":"wiki-investment-senolytic-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-senolytic-therapeutics"},{"source_artifact_id":"wiki-investment-er-stress-upr-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-er-stress-upr-therapeutics"},{"source_artifact_id":"wiki-investment-adult-neurogenesis-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-adult-neurogenesis-therapeutics"},{"source_artifact_id":"wiki-investment-4r-tauopathy-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-4r-tauopathy-therapeutics"},{"source_artifact_id":"wiki-investment-protein-aggregation-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-protein-aggregation-therapeutics"},{"source_artifact_id":"wiki-investment-complement-system-therapeutics-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-complement-system-therapeutics-neurodegeneration"},{"source_artifact_id":"wiki-investment-pyroptosis-inhibitors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 19x in wiki/investment-pyroptosis-inhibitors-neurodegeneration"},{"source_artifact_id":"wiki-investment-mitochondrial-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-mitochondrial-therapeutics"},{"source_artifact_id":"wiki-investment-heat-shock-protein-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-heat-shock-protein-therapeutics"},{"source_artifact_id":"wiki-investment-glp-1-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-glp-1-therapeutics"},{"source_artifact_id":"wiki-investment-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/investment-neuroinflammation"},{"source_artifact_id":"wiki-investment-rna-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-rna-therapeutics"},{"source_artifact_id":"wiki-investment-anti-tau-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-anti-tau-therapeutics"},{"source_artifact_id":"wiki-investment-amyloid-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-amyloid-therapeutics"},{"source_artifact_id":"wiki-investment-neuroinflammation-therapeutics","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/investment-neuroinflammation-therapeutics"},{"source_artifact_id":"wiki-investment-lysosomal-dysfunction-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-lysosomal-dysfunction-therapeutics"},{"source_artifact_id":"wiki-cell-types-globus-pallidus-internus-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-globus-pallidus-internus-pd"},{"source_artifact_id":"wiki-cell-types-microglia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/cell-types-microglia"},{"source_artifact_id":"wiki-cell-types-iron-laden-microglia","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-iron-laden-microglia"},{"source_artifact_id":"wiki-cell-types-nigrostriatal-dopamine-terminals-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-nigrostriatal-dopamine-terminals-pd"},{"source_artifact_id":"wiki-cell-types-substantia-nigra-neurons-progressive-supranuclear-palsy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-substantia-nigra-neurons-progressive-supranuclear-palsy"},{"source_artifact_id":"wiki-cell-types-microglia-primed","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-microglia-primed"},{"source_artifact_id":"wiki-cell-types-mitochondrial-dysfunction-dopaminergic","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-mitochondrial-dysfunction-dopaminergic"},{"source_artifact_id":"wiki-cell-types-melanocytes-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-melanocytes-pd"},{"source_artifact_id":"wiki-cell-types-reactive-astrocytes-a2","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/cell-types-reactive-astrocytes-a2"},{"source_artifact_id":"wiki-cell-types-snc-dopamine-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-snc-dopamine-pd"},{"source_artifact_id":"wiki-cell-types-amyloid-beta-exposed","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-amyloid-beta-exposed"},{"source_artifact_id":"wiki-cell-types-p2x3-receptor-neurons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-p2x3-receptor-neurons"},{"source_artifact_id":"wiki-cell-types-amyloid-beta-cortical-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-amyloid-beta-cortical-neurons"},{"source_artifact_id":"wiki-cell-types-microglia-in-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/cell-types-microglia-in-neuroinflammation"},{"source_artifact_id":"wiki-cell-types-necroptotic-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/cell-types-necroptotic-neurons"},{"source_artifact_id":"wiki-cell-types-dopaminergic-vta-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-dopaminergic-vta-pd"},{"source_artifact_id":"wiki-cell-types-dorsal-raphe-serotonergic-neurons-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-dorsal-raphe-serotonergic-neurons-pd"},{"source_artifact_id":"wiki-cell-types-nigral-microglia-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/cell-types-nigral-microglia-parkinsons"},{"source_artifact_id":"wiki-cell-types-vulnerable-dopaminergic-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-vulnerable-dopaminergic-pd"},{"source_artifact_id":"wiki-cell-types-p2x7-receptor-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/cell-types-p2x7-receptor-neurons"},{"source_artifact_id":"wiki-cell-types-crf-corticoliberin-neurons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-crf-corticoliberin-neurons"},{"source_artifact_id":"wiki-cell-types-amyloid-beta-exposed-neurons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-amyloid-beta-exposed-neurons"},{"source_artifact_id":"wiki-cell-types-apoe4-homozygous-astrocytes","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-apoe4-homozygous-astrocytes"},{"source_artifact_id":"wiki-cell-types-neuroinflammation-microglia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/cell-types-neuroinflammation-microglia"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-neuroinflammation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-cross-disease-neuroinflammation-mechanisms","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-cross-disease-neuroinflammation-mechanisms"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 20x in wiki/mechanisms-neuroinflammation-pd"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-dysfunction-ftd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-neuroimmune-dysfunction-ftd"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-pd-dementia-with-lewy-bodies","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-neuroinflammation-pd-dementia-with-lewy-bodies"},{"source_artifact_id":"wiki-mechanisms-ceramide-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-ceramide-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-complement-system-activation-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-complement-system-activation-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-pd-cure-roadmap","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-pd-cure-roadmap"},{"source_artifact_id":"wiki-mechanisms-investment-signal-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-investment-signal-synthesis"},{"source_artifact_id":"wiki-mechanisms-cbs-psp-panxoneopathy-membrane-biology","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 14x in wiki/mechanisms-cbs-psp-panxoneopathy-membrane-biology"},{"source_artifact_id":"wiki-mechanisms-hmgb1-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-hmgb1-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-synaptic-dysfunction-hypothesis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-synaptic-dysfunction-hypothesis"},{"source_artifact_id":"wiki-mechanisms-hypoxia-response","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-hypoxia-response"},{"source_artifact_id":"wiki-mechanisms-amyloid-beta-cellular-uptake","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-amyloid-beta-cellular-uptake"},{"source_artifact_id":"wiki-mechanisms-nf-kb-signaling-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-nf-kb-signaling-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-nfkb-signaling-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-nfkb-signaling-pathway"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-checkpoint-metal-oxidative-convergence-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/mechanisms-neuroimmune-checkpoint-metal-oxidative-convergence-synthesis"},{"source_artifact_id":"wiki-mechanisms-tlr-signaling-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-tlr-signaling-parkinsons"},{"source_artifact_id":"wiki-mechanisms-ginsenosides-neuroprotection-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-ginsenosides-neuroprotection-parkinsons"},{"source_artifact_id":"wiki-mechanisms-advanced-glycation-end-products","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-advanced-glycation-end-products"},{"source_artifact_id":"wiki-mechanisms-mtor-autophagy-lysosome-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-mtor-autophagy-lysosome-pathway"},{"source_artifact_id":"wiki-mechanisms-tau-kinase-signaling-cascade","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-tau-kinase-signaling-cascade"},{"source_artifact_id":"wiki-mechanisms-gene-mechanism-therapy-causal-chains","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-gene-mechanism-therapy-causal-chains"},{"source_artifact_id":"wiki-mechanisms-pyroptosis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-pyroptosis"},{"source_artifact_id":"wiki-mechanisms-convergent-molecular-mechanisms","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-convergent-molecular-mechanisms"},{"source_artifact_id":"wiki-mechanisms-microglia-neuron-metabolic-crosstalk","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglia-neuron-metabolic-crosstalk"},{"source_artifact_id":"wiki-mechanisms-protein-o-glcna-cylation-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-protein-o-glcna-cylation-pathway"},{"source_artifact_id":"wiki-mechanisms-g-proteins","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-g-proteins"},{"source_artifact_id":"wiki-mechanisms-psp-mitochondrial-dysfunction","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-psp-mitochondrial-dysfunction"},{"source_artifact_id":"wiki-mechanisms-cbs-pyroptosis-inflammasome-activation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 41x in wiki/mechanisms-cbs-pyroptosis-inflammasome-activation"},{"source_artifact_id":"wiki-mechanisms-pkr-pathway-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-pkr-pathway-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-purinergic-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-purinergic-signaling"},{"source_artifact_id":"wiki-mechanisms-pink1-parkin-mitophagy-pd-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-pink1-parkin-mitophagy-pd-causal-chain"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-causal-reactive-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-neuroinflammation-causal-reactive-parkinsons"},{"source_artifact_id":"wiki-mechanisms-autophagy-lysosomal-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-autophagy-lysosomal-alzheimers"},{"source_artifact_id":"wiki-mechanisms-als-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-als-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-homocysteine-neurotoxicity","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-homocysteine-neurotoxicity"},{"source_artifact_id":"wiki-mechanisms-amyloid-conformational-strains","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-amyloid-conformational-strains"},{"source_artifact_id":"wiki-mechanisms-sex-specific-mechanisms-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-sex-specific-mechanisms-parkinsons"},{"source_artifact_id":"wiki-mechanisms-neuronal-death-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-neuronal-death-ad"},{"source_artifact_id":"wiki-mechanisms-cortisol-tau-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-cortisol-tau-pathway"},{"source_artifact_id":"wiki-mechanisms-sex-specific-mechanisms-alzheimers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-sex-specific-mechanisms-alzheimers"},{"source_artifact_id":"wiki-mechanisms-parkinsons-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-parkinsons-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-mtor-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-mtor-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-endocannabinoid-system","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-endocannabinoid-system"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-interface","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 16x in wiki/mechanisms-neuroimmune-interface"},{"source_artifact_id":"wiki-mechanisms-gasotransmitters-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-gasotransmitters-neuroprotection"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-hypothesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-neuroinflammation-hypothesis"},{"source_artifact_id":"wiki-mechanisms-galectin-3-mechanism-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-galectin-3-mechanism-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-investment-evidence-convergence-analysis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-investment-evidence-convergence-analysis"},{"source_artifact_id":"wiki-mechanisms-microglial-priming-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglial-priming-pathway"},{"source_artifact_id":"wiki-mechanisms-bbb-neuroimmune-interface-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-bbb-neuroimmune-interface-cbs-psp"},{"source_artifact_id":"wiki-mechanisms-ad-pd-shared-pathways","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-ad-pd-shared-pathways"},{"source_artifact_id":"wiki-mechanisms-amyloid-tau-synergistic-interaction-hypothesis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-amyloid-tau-synergistic-interaction-hypothesis"},{"source_artifact_id":"wiki-mechanisms-glia-neuron-crosstalk-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-glia-neuron-crosstalk-ad"},{"source_artifact_id":"wiki-mechanisms-short-chain-fatty-acids","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-short-chain-fatty-acids"},{"source_artifact_id":"wiki-mechanisms-viral-post-infectious-als","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-viral-post-infectious-als"},{"source_artifact_id":"wiki-mechanisms-4r-tauopathies-neuroimmune-comparison","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-4r-tauopathies-neuroimmune-comparison"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 23x in wiki/mechanisms-neuroinflammation-comparison"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-neuroinflammation-pathway"},{"source_artifact_id":"wiki-mechanisms-convergent-pathways-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-convergent-pathways-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-amyloid-oligomers-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-amyloid-oligomers-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-dna-sensing-pathways-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-dna-sensing-pathways-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-microglial-dysfunction-hypothesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-microglial-dysfunction-hypothesis"},{"source_artifact_id":"wiki-mechanisms-syk-kinase-microglial-activation-alzheimers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-syk-kinase-microglial-activation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-rage-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-rage-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-pyroptosis-signaling-pathway-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 25x in wiki/mechanisms-pyroptosis-signaling-pathway-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-trem2-cytokine-regulation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-trem2-cytokine-regulation"},{"source_artifact_id":"wiki-mechanisms-target-family-consolidation-analysis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-target-family-consolidation-analysis"},{"source_artifact_id":"wiki-mechanisms-ftd-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-ftd-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-fgf13-mtch2-neuroprotection-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-fgf13-mtch2-neuroprotection-parkinsons"},{"source_artifact_id":"wiki-mechanisms-microglia-disease-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-microglia-disease-comparison"},{"source_artifact_id":"wiki-mechanisms-emerging-therapeutic-directions","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-emerging-therapeutic-directions"},{"source_artifact_id":"wiki-mechanisms-microglial-polarization","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-microglial-polarization"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-protein-oligomerization-toxicity-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-protein-oligomerization-toxicity-pathway"},{"source_artifact_id":"wiki-mechanisms-trem2-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-trem2-signaling"},{"source_artifact_id":"wiki-mechanisms-psychobiotic-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-psychobiotic-therapy-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-microglia-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-neuroinflammation-microglia-pathway"},{"source_artifact_id":"wiki-mechanisms-mitochondrial-dysfunction-glial-cells","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-mitochondrial-dysfunction-glial-cells"},{"source_artifact_id":"wiki-mechanisms-cross-disease-shared-pathways-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-cross-disease-shared-pathways-synthesis"},{"source_artifact_id":"wiki-mechanisms-psp-pyroptosis-inflammasome-activation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 35x in wiki/mechanisms-psp-pyroptosis-inflammasome-activation"},{"source_artifact_id":"wiki-mechanisms-cbs-microglial-neuroimmune-axis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-cbs-microglial-neuroimmune-axis"},{"source_artifact_id":"wiki-mechanisms-omega-3-fatty-acid-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-omega-3-fatty-acid-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-cbs-er-stress","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cbs-er-stress"},{"source_artifact_id":"wiki-mechanisms-ad-pd-neuroinflammation-comparison-matrix","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-ad-pd-neuroinflammation-comparison-matrix"},{"source_artifact_id":"wiki-mechanisms-sirtuin-signaling-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-sirtuin-signaling-pathway"},{"source_artifact_id":"wiki-mechanisms-innate-immune-signaling-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/mechanisms-innate-immune-signaling-ad"},{"source_artifact_id":"wiki-mechanisms-melatonin-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-melatonin-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-neuroinflammation-ad-pathway"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-inhibitors-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-cgas-sting-inhibitors-parkinsons"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/mechanisms-neuroinflammation-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-innate-immune-response","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-innate-immune-response"},{"source_artifact_id":"wiki-mechanisms-emerging-therapeutic-directions-2025-2026","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-emerging-therapeutic-directions-2025-2026"},{"source_artifact_id":"wiki-mechanisms-senostatic-therapies-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-senostatic-therapies-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-nf-kappa-b-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-nf-kappa-b-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-mlcs-quantification-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-mlcs-quantification-pd"},{"source_artifact_id":"wiki-mechanisms-necroptosis-alzheimers-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-necroptosis-alzheimers-disease"},{"source_artifact_id":"wiki-mechanisms-metaflammation-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-metaflammation-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-tea-polyphenols-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-tea-polyphenols-neuroprotection"},{"source_artifact_id":"wiki-mechanisms-senescence-therapeutic-targeting","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-senescence-therapeutic-targeting"},{"source_artifact_id":"wiki-mechanisms-alzheimers-pathogenesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-alzheimers-pathogenesis"},{"source_artifact_id":"wiki-mechanisms-fibrinogen-integrin-alpha-synuclein-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-fibrinogen-integrin-alpha-synuclein-pd"},{"source_artifact_id":"wiki-mechanisms-precision-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-precision-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-microglial-metabolic-reprogramming","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglial-metabolic-reprogramming"},{"source_artifact_id":"wiki-mechanisms-hydrogen-sulfide-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-hydrogen-sulfide-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-tlr-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-tlr-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-brain-endothelial-cell-dysfunction-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-brain-endothelial-cell-dysfunction-pathway"},{"source_artifact_id":"wiki-mechanisms-chemokine-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-chemokine-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-calcium-dysregulation-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-calcium-dysregulation-comparison"},{"source_artifact_id":"wiki-mechanisms-connexin-hemichannel-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-connexin-hemichannel-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-gba-parkinson-risk","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-gba-parkinson-risk"},{"source_artifact_id":"wiki-mechanisms-innate-immune-pattern-recognition-4r-tauopathies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 29x in wiki/mechanisms-innate-immune-pattern-recognition-4r-tauopathies"},{"source_artifact_id":"wiki-mechanisms-stroke-neurodegeneration-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-stroke-neurodegeneration-pathway"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-mitochondria-crosstalk","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 33x in wiki/mechanisms-neuroinflammation-mitochondria-crosstalk"},{"source_artifact_id":"wiki-mechanisms-jnk-p38-mapk-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-jnk-p38-mapk-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-anti-amyloid-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-anti-amyloid-therapeutics"},{"source_artifact_id":"wiki-mechanisms-therapeutic-synergy-combination-rankings","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-therapeutic-synergy-combination-rankings"},{"source_artifact_id":"wiki-mechanisms-inflammaging-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-inflammaging-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-tlr5-microglia-neuroinflammation-hypothesis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-tlr5-microglia-neuroinflammation-hypothesis"},{"source_artifact_id":"wiki-mechanisms-cross-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-cross-disease"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad-pd-als","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/mechanisms-neuroinflammation-ad-pd-als"},{"source_artifact_id":"wiki-mechanisms-psp-tau-caspase-cleavage-truncation","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-psp-tau-caspase-cleavage-truncation"},{"source_artifact_id":"wiki-mechanisms-microglial-neuronal-tauopathies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglial-neuronal-tauopathies"},{"source_artifact_id":"wiki-mechanisms-inpp5d-ship1-dysfunction-neuroinflammation-ad-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-inpp5d-ship1-dysfunction-neuroinflammation-ad-causal-chain"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-cross-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 22x in wiki/mechanisms-neuroinflammation-cross-disease"},{"source_artifact_id":"wiki-mechanisms-optn-mitophagy-neurodegeneration-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-optn-mitophagy-neurodegeneration-causal-chain"},{"source_artifact_id":"wiki-mechanisms-nrti-immunomodulation-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 26x in wiki/mechanisms-nrti-immunomodulation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-neuroinflammation-ad-pd"},{"source_artifact_id":"wiki-mechanisms-aging-to-ad-switch-trigger","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-aging-to-ad-switch-trigger"},{"source_artifact_id":"wiki-mechanisms-glucocorticoid-signaling-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-glucocorticoid-signaling-pathway"},{"source_artifact_id":"wiki-mechanisms-panoptosis-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/mechanisms-panoptosis-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-cytokine-storm-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 31x in wiki/mechanisms-cytokine-storm-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neurovascular-gut-brain-axis-neurodegeneration-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-neurovascular-gut-brain-axis-neurodegeneration-synthesis"},{"source_artifact_id":"wiki-mechanisms-extracellular-vesicles-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-extracellular-vesicles-parkinsons"},{"source_artifact_id":"wiki-mechanisms-pd-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-pd-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-dashboard","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-dashboard"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 25x in wiki/mechanisms-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-flavonoids-alpha-synuclein-aggregation","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-flavonoids-alpha-synuclein-aggregation"},{"source_artifact_id":"wiki-mechanisms-syk-microglial-activation-alzheimers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-syk-microglial-activation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-peripheral-immune-infiltration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-peripheral-immune-infiltration"},{"source_artifact_id":"wiki-mechanisms-gadd45g-pathological-sensor-gliosis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-gadd45g-pathological-sensor-gliosis"},{"source_artifact_id":"wiki-mechanisms-pd-neuroinflammation-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-pd-neuroinflammation-pathway"},{"source_artifact_id":"wiki-mechanisms-parkinsons-disease-mechanisms","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-parkinsons-disease-mechanisms"},{"source_artifact_id":"wiki-mechanisms-network-pharmacology-neurodegeneration-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-network-pharmacology-neurodegeneration-synthesis"},{"source_artifact_id":"wiki-mechanisms-sasp-senescence-associated-secretory-phenotype","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-sasp-senescence-associated-secretory-phenotype"},{"source_artifact_id":"wiki-mechanisms-pannexin-p2x7-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 19x in wiki/mechanisms-pannexin-p2x7-signaling"},{"source_artifact_id":"wiki-mechanisms-gba1-gcase-lysosome-pd-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-gba1-gcase-lysosome-pd-causal-chain"},{"source_artifact_id":"wiki-mechanisms-gsk3-beta","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-gsk3-beta"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cgas-sting-parkinsons"},{"source_artifact_id":"wiki-mechanisms-small-molecule-derivatives-neurodegenerative-pathways","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-small-molecule-derivatives-neurodegenerative-pathways"},{"source_artifact_id":"wiki-mechanisms-cryptoxanthin-neuroprotection","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cryptoxanthin-neuroprotection"},{"source_artifact_id":"wiki-mechanisms-microglial-state-trajectory-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-microglial-state-trajectory-ad"},{"source_artifact_id":"wiki-mechanisms-glial-neuron-crosstalk-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-glial-neuron-crosstalk-parkinsons"},{"source_artifact_id":"wiki-mechanisms-aging-vs-neurodegeneration-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-aging-vs-neurodegeneration-comparison"},{"source_artifact_id":"wiki-mechanisms-integrated-stress-response-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-integrated-stress-response-ad"},{"source_artifact_id":"wiki-mechanisms-microglia-activation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-microglia-activation"},{"source_artifact_id":"wiki-mechanisms-calcium-signaling-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-calcium-signaling-ad"},{"source_artifact_id":"wiki-mechanisms-huntingtin-mitochondrial-dysfunction","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-huntingtin-mitochondrial-dysfunction"},{"source_artifact_id":"wiki-mechanisms-autophagy-lysosomal-ad","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-autophagy-lysosomal-ad"},{"source_artifact_id":"wiki-mechanisms-nfkb-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-nfkb-signaling"},{"source_artifact_id":"wiki-mechanisms-overview","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-overview"},{"source_artifact_id":"wiki-mechanisms-complement-system-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-complement-system-pathway"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cgas-sting-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 15x in wiki/mechanisms-neuroinflammation-parkinsons"},{"source_artifact_id":"wiki-mechanisms-sirt1-alzheimer-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-sirt1-alzheimer-pathway"},{"source_artifact_id":"wiki-mechanisms-mechanism-categories-pathways","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-mechanism-categories-pathways"},{"source_artifact_id":"wiki-mechanisms-trem2","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-trem2"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 16x in wiki/mechanisms-neuroinflammation-ad"},{"source_artifact_id":"wiki-mechanisms-glp-1-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-glp-1-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-therapeutic-targetability-rankings","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-therapeutic-targetability-rankings"},{"source_artifact_id":"wiki-mechanisms-alzheimers-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 14x in wiki/mechanisms-alzheimers-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-purinergic-signaling-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-purinergic-signaling-parkinsons"},{"source_artifact_id":"wiki-mechanisms-pyroptosis-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 33x in wiki/mechanisms-pyroptosis-neurodegeneration"},{"source_artifact_id":"wiki-technologies-digital-therapeutics-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/technologies-digital-therapeutics-pd"},{"source_artifact_id":"wiki-technologies-digital-biomarkers-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-digital-biomarkers-pd"},{"source_artifact_id":"wiki-technologies-wearable-sensors-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-wearable-sensors-pd"},{"source_artifact_id":"wiki-technologies-rna-editing-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-rna-editing-therapeutics"},{"source_artifact_id":"wiki-technologies-digital-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-digital-therapeutics"},{"source_artifact_id":"wiki-technologies-ai-movement-analysis-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-ai-movement-analysis-pd"},{"source_artifact_id":"wiki-biomarkers-interleukin-1-beta-il1b","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/biomarkers-interleukin-1-beta-il1b"},{"source_artifact_id":"wiki-biomarkers-neuroimmune-psp-biomarkers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/biomarkers-neuroimmune-psp-biomarkers"},{"source_artifact_id":"wiki-biomarkers-amyloid-beta-40-abeta-40","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/biomarkers-amyloid-beta-40-abeta-40"},{"source_artifact_id":"wiki-biomarkers-interleukin-18-il18","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/biomarkers-interleukin-18-il18"},{"source_artifact_id":"wiki-biomarkers-alpha-synuclein-seed-kinetics-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/biomarkers-alpha-synuclein-seed-kinetics-pd"},{"source_artifact_id":"wiki-events-mds-2026-neuroprotection-neurorestorative-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/events-mds-2026-neuroprotection-neurorestorative-parkinsons"},{"source_artifact_id":"wiki-entities-amyloid-pet","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/entities-amyloid-pet"},{"source_artifact_id":"wiki-entities-xpro1595","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/entities-xpro1595"},{"source_artifact_id":"wiki-entities-aria-imaging","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/entities-aria-imaging"},{"source_artifact_id":"wiki-gaps-priority-research-areas","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/gaps-priority-research-areas"},{"source_artifact_id":"wiki-companies-ad-rna-therapeutics","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/companies-ad-rna-therapeutics"},{"source_artifact_id":"wiki-experiments-alpha-synuclein-aggregation-triggers-sporadic-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-alpha-synuclein-aggregation-triggers-sporadic-pd"},{"source_artifact_id":"wiki-experiments-prion-strain-selective-vulnerability","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-prion-strain-selective-vulnerability"},{"source_artifact_id":"wiki-experiments-glp1-responder-prediction-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-glp1-responder-prediction-pd"},{"source_artifact_id":"wiki-experiments-alpha-syn-saa-kinetics-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-alpha-syn-saa-kinetics-pd"},{"source_artifact_id":"wiki-experiments-synaptic-mitochondrial-resilience-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-synaptic-mitochondrial-resilience-pd"},{"source_artifact_id":"wiki-experiments-alpha-synuclein-spreading-neurodegeneration-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-alpha-synuclein-spreading-neurodegeneration-pd"},{"source_artifact_id":"wiki-experiments-combination-therapy-sequencing-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-combination-therapy-sequencing-pd"},{"source_artifact_id":"wiki-experiments-dopaminergic-neuron-selective-vulnerability-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-dopaminergic-neuron-selective-vulnerability-pd"},{"source_artifact_id":"wiki-experiments-microglial-immune-hd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-microglial-immune-hd"},{"source_artifact_id":"wiki-organizations-denali-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/organizations-denali-therapeutics"},{"source_artifact_id":"wiki-diseases-alzheimers-disease","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/diseases-alzheimers-disease"},{"source_artifact_id":"wiki-diseases-corticobasal-syndrome","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/diseases-corticobasal-syndrome"},{"source_artifact_id":"wiki-diseases-atypical-parkinsonism","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/diseases-atypical-parkinsonism"},{"source_artifact_id":"wiki-diseases-cerebral-amyloid-angiopathy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/diseases-cerebral-amyloid-angiopathy"},{"source_artifact_id":"wiki-diseases-frontotemporal-dementia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/diseases-frontotemporal-dementia"},{"source_artifact_id":"wiki-diseases-investment-landscape-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/diseases-investment-landscape-parkinsons"},{"source_artifact_id":"wiki-diseases-autism","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/diseases-autism"},{"source_artifact_id":"wiki-ai-tool-storm-stanford","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ai-tool-storm-stanford"},{"source_artifact_id":"wiki-cell-types-neuroinflammation-sensitive-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-neuroinflammation-sensitive-neurons"}],"current_artifact_id":"experiment-exp-9d2d59a7-8bc0-4399-aab0-2538f3a07b6f","is_canonical":true,"supersede_chain":["experiment-exp-9d2d59a7-8bc0-4399-aab0-2538f3a07b6f"]}